Substitution therapy for alcoholism: Time for a reappraisal?

Journal of Psychopharmacology

Volumn 26, Issue 2, 2012, Pages 205-212

  Chick, Jonathan ^a   Nutt, David J ^b  

^a QUEEN MARGARET UNIVERSITY   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Alcohol; alcohol dependence; baclofen; benzodiazepines; GABA A receptors; GABAB receptors; GHB; sodium oxybate; substitution therapy

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ALCOHOL; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CLOMETHIAZOLE; DIAZEPAM; FLUNITRAZEPAM; GABAPENTIN; LORAZEPAM; NALTREXONE; OXYBATE SODIUM; PLACEBO; PREGABALIN; TIAGABINE; VIGABATRIN;

ALCOHOL ABSTINENCE; ALCOHOLISM; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; MORBIDITY; MORTALITY; MUSCLE WEAKNESS; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; SOMNOLENCE; SUBSTITUTION THERAPY; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ALCOHOLISM; ANTICONVULSANTS; BENZODIAZEPINES; BRAIN; CHLORMETHIAZOLE; DRUG TOXICITY; GABA-B RECEPTOR AGONISTS; HARM REDUCTION; HUMANS; SODIUM OXYBATE;

EID: 84856431590     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111408463     Document Type: Review

References (75)

1. Abanades S, Farré M, Barral D, Torrens M, Closas N, Langohr K, et al. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users. J Clin Psychopharmacol. 2007 ; 27: 625-638 (Pubitemid 351339451)
2. Calling time: the nation's drinking as a major health issue. London: Academy of Medical Sciences ; 2004 :
3. Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G. Ability of baclofen in reducing alcohol craving and intake: II. Preliminary clinical evidence. Alcohol Clin Exp Res. 2000 ; 24: 67-71 (Pubitemid 30062783)
4. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002a ; 37: 504-508
5. Addolorato G, Caputo F, Capristo E, Janiri L, Bernardi M, Agabio R, et al. Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med. 2002b ; 112: 226-229
6. Addolorato G, Castelli E, Stefanini GF, Casella G, Caputo F, Marsigli L, et al. An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. Alcohol Alcohol. 1996 ; 31: 341-345 (Pubitemid 26302563)
7. Addolorato G, Cibin M, Caprista E, Beghè F, Gessa GL, Stefanini GF, et al. Maintaining abstinence from alcohol with gamma-hydroxybutyric acid. Lancet. 1998a ; 351: 38 (Pubitemid 28020172)
8. Addolorato G, Cibin M, Caputo F, Capristo E, Gessa GL, Stefanini GF, et al. Gamma-hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility in non-responder alcoholic patients. Drug Alcohol Dep. 1998b ; 53: 7-10 (Pubitemid 128712675)
9. Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med. 2006 ; 119: 276.e13 - e18
10. Addolorato G, Leggio L, Abenavoli L, DeLorenzi G, Parente A, Caputo F, et al. Suppression of alcohol delirium tremens by baclofen administration: a case report. Clin Neuropharmacol. 2003 ; 26: 258-262 (Pubitemid 37221637)
11. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomized, double-blind controlled study. Lancet. 2007 ; 370: 1915-1922 (Pubitemid 350192657)
12. Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Gasbarrini G, et al. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol-dependent subjects: secondary analysis of a randomized double-blind placebo-controlled trial. Alcohol Alcohol. 2011 ; 46: 312-317
13. Agabio R, Colombo GC, Loche A, Lobina C, Pani RL, Reali R, et al. γ-hydroxybutyric acid reducing effect on ethanol intake: evidence in favour of a substitution mechanism. Alcohol Alcohol. 1998 ; 33: 465-474 (Pubitemid 28477179)
14. Agabio R, Marras P, Addolorato G, Carpiniello B, Gessa GL. Baclofen suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: a case report. J Clin Psychopharmacol. 2007 ; 27: 319-320 (Pubitemid 46763329)
15. Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol. 2005 ; 40: 147-150 (Pubitemid 40347343)
16. Benzodiazepine dependence, toxicity, and abuse: a task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association ; 1990 :
17. Bowery NG, Hill DR, Hudson AL, Doble A, Middlemiss DN, Shaw J, et al. Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature. 1980 ; 283: 92-94 (Pubitemid 10170892)
18. Brebner K, Ahn S, Phillips AG. Attenuation of d-amphetamine self-administration by baclofen in the rat: behavioral and neurochemical correlates. Psychopharmacology (Berl). 2005 ; 177: 409-417 (Pubitemid 40228287)
19. Bucknam W. Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol. 2007 ; 42: 158-160 (Pubitemid 47072109)
20. Caputo F. γ-Hydroxybutyrate (GHB) for the Treatment of Alcohol Dependence: a Call for Further Understanding. Alcohol Alcohol. 2011 ; 46: 3
21. Caputo F, Addolorato G, Lorenzini F, Domenicali M, Greco G, del RE A, et al. Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. Drug Alcohol Depend. 2003 ; 70: 85-91 (Pubitemid 36385156)
22. Caputo F, Addolorato G, Stoppo M, Francini S, Vignoli T, Lorenzini F, et al. Comparing and combining gammahydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomized comparative study. Eur Neuropsychopharmacol. 2007 ; 17: 781-789 (Pubitemid 47588865)
23. Caputo F, Vignoli T, Maremmani I, Bernardi M, Zoli G. Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: a review. Int J Environ Res Public Health. 2009 ; 6: 1917-1929
24. Carter LP, Pardi D, Gorsline J, Griffiths RR. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend. 2009 ; 104: 1-10
25. Cash CD, Gobaille S, Kemmel V, Andriamampandry C, Maitre M. Gamma-hydroxybutyrate receptor function studied by the modulation of nitric oxide synthase activity in rat frontal cortex punches. Biochem Pharmacol. 1999 ; 58: 1815-1819 (Pubitemid 29505423)
26. Castells X, Casas M, Pérez-Mañá C, Roncero C, Vidal X, Capellà D. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2010 ; 2: CD007380
27. Castells X, Casas M, Vidal X, Bosch R, Roncero C, Ramos-Quiroga JA, et al. Efficacy of central nervous system stimulant treatment for cocaine dependence: a systematic review and meta-analysis of randomized controlled clinical trials. Addiction. 2007 ; 102: 1871-1887
28. Ciraulo DA, Sands BF, Shader RI. Critical review of liability for benzodiazepine abuse among alcoholics. Am J Psychiatry. 1988 ; 145: 1501-1506 (Pubitemid 19009695)
29. Cowen PJ, Nutt DJ. Abstinence symptoms after withdrawal of tranquillising drugs: is there a common neurochemical mechanism?. Lancet. 1982 ; 2 (8294). 360-362 (Pubitemid 12093051)
30. Craig K, Gomez HF, McManus JL, Bania TC. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med. 2000 ; 18: 65-70 (Pubitemid 30029188)
31. Deutsch JA, Walton NY. Diazepam maintenance of alcohol preference during alcohol withdrawal. Science. 1977 ; 198: 307-309 (Pubitemid 8209679)
32. Evans SM, Bisaga A. Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcohol Clin Exp Res. 2009 ; 33: 19-30
33. Fink-Jensen A, Suzdak PD, Swedberg MD, Judge ME, Hansen L, Nielsen PG. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol. 1992 ; 220: 197-201
34. Flannery BA, Garbutt JC, Cody MW, Renn W, Grace K, Osborne M, et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res. 2004 ; 28: 1517-1523 (Pubitemid 39390473)
35. Gallimberti L, Ferri M, Ferrara SD, Fadda F, Gessa GL. gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res. 1992 ; 16: 673-676
36. Garbutt JC. The state of pharmacotherapy for the treatment of alcohol dependence. J Subst Abuse Treat. 2009 ; 36: S15 - S25
37. Glue P, Nutt D. Overexcitement and disinhibition. Dynamic neurotransmitter interactions in alcohol withdrawal. Br J Psychiatry. 1990 ; 157: 491-499 (Pubitemid 20335960)
38. Gonzalez A, Nutt DJ. Gammahydoxybutyrate abuse and dependency. J Psychopharmacol. 2005 ; 19: 195-204
39. Hedlund L, Wahlström G. The effect of diazepam on voluntary ethanol intake in a rat model of alcoholism. Alcohol Alcohol. 1998 ; 33: 207-219 (Pubitemid 28241491)
40. Heydtmann M. Baclofen effect related to liver damage. Alcohol Clin Exp Res. 2011 ; 35: 848
41. Information Services Division. (2009) Alcohol Statistics Scotland 2009. Edinburgh, ISD. Available at: http://www.alcoholinformation.isdscotland.org/ alcohol-misuse/files/alcohol-stats-bul-09.pdf (accessed 16 June 2011).
42. Jackson A, Stephens DN, Duka T. Lorazepam substitutes for the alcohol stimulus in social drinkers. Psychopharmacology (Berl). 2003 ; 166: 181-187 (Pubitemid 36313126)
43. A receptors in the actions of alcohol and in alcoholism: recent advances. Alcohol Alcohol. 1994 ; 29: 115-129
44. Lejoyeux M, Solomon J, Adès J. Benzodiazepine treatment for alcohol-dependent patients. Alcohol Alcohol. 1998 ; 33: 563-575 (Pubitemid 28548383)
45. Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet. 2006 ; 367: 52-56 (Pubitemid 43038670)
46. Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev. 2010 ; 2: CD006266
47. LeTourneau JL, Hagg DS, Smith SM. Baclofen and gamma-hydroxybutyrate withdrawal. Neurocrit Care. 2008 ; 8: 430-433
48. Lingenhoehl K, Brom R, Heid J, Beck P, Froestl W, Kaupmann K, et al. Gamma-hydroxybutyrate is a weak agonist at recombinant GABA(B) receptors. Neuropharmacology. 1999 ; 38: 1667-1673 (Pubitemid 29430241)
49. Lingford-Hughes AR, Welch S, Nutt DJ. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity. J Psychopharmacol. 2004 ; 18: 293-335
50. Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med. 2002 ; 17: 349-355 (Pubitemid 34626103)
51. Martinotti G, di Nicola M, Frustaci A, Romanelli R, Tedeschi D, Guglielmo R, et al. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. Addiction. 2010 ; 105: 288-299
52. Minozzi S, Amato L, Vecchi S, Davoli M. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev. 2010 ; 3: CD005064
53. Miotto K, Darakjian J, Basch J, Murray S, Zogg J, Rawson R. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict. 2001 ; 10: 232-241 (Pubitemid 32879089)
54. Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009 ; 33: 1582-1588
55. Myrick H, Taylor B, LaRowe S, Nguyen S, Boyle E, Cochran K, et al. A retrospective chart review comparing tiagabine and benzodiazepines for the treatment of alcohol withdrawal. J Psychoactive Drugs. 2005 ; 37: 409-414 (Pubitemid 43152745)
56. Mueller TI, Pagano ME, Rodriguez BF, Bruce SE, Stout RL, Keller MB. Long-term use of benzodiazepines in participants with comorbid anxiety and alcohol use disorders. Alcohol Clin Exp Res. 2005 ; 29: 1411-1418 (Pubitemid 41243365)
57. NICE (2011) Alcohol use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. Retrieved from: http://guidance. nice.org.uk/CG115 (accessed 16 June 2010).
58. NHS (2010) Statistics on Alcohol, England 2010Retrieved from: http://www.ic.nhs.uk/pubs/alcohol10 (accessed 16 June 2010).
59. Nutt D. Alcohol and the brain. Pharmacological insights for psychiatrists. Br J Psychiatry. 1999 ; 175: 114-119 (Pubitemid 29359372)
60. Nutt DJ, Malizia AL. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry. 2001 ; 179: 390-396 (Pubitemid 33097160)
61. Poulos CX, Zack M. Low-dose diazepam primes motivation for alcohol and alcohol-related semantic networks in problem drinkers. Behav Pharmacol. 2004 ; 15: 503-512 (Pubitemid 39482939)
62. Benzodiazepines: risks, benefits or dependence: a re-evaluation. The Royal College of Psychiatrists Council Report CR59. London: Royal College of Psychiatrists ; 1997 :
63. Sewell RA, Petrakis IL. Does Gamma-Hydroxybutyrate (GHB) Have a Role in the Treatment of Alcoholism?. Alcohol Alcohol. 2011 ; 46: 1-2
64. Snead OC, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med. 2005 ; 352: 2721-2732
65. Stuppaeck CH, Deisenhammer EA, Kurz M, Whitworth AB, Hinterhuber H. The irreversible gamma-aminobutyrate transaminase inhibitor vigabatrin in the treatment of the alcohol withdrawal syndrome. Alcohol Alcohol. 1996 ; 31: 109-111 (Pubitemid 26096826)
66. Soufia M, Plaze M, Gueguen B, Demigneux G, Olié JP, Gaillard R. Behavioral Disinhibition With Baclofen. J Clin Psychopharmacol. 2010 ; 30: 759-760
67. The Health and Social Care Information Centre. Statistics on Alcohol i England, 2010, http://www.ic.nhs.uk/webfiles/publications/alcohol10/Statistics- on-Alcohol-England-2010.pdf (accessed 16 June 2011).
68. Tyacke RJ, Lingford-Hughes A, Reed LJ, Nutt DJ. GABAB receptors in addiction and its treatment. GABABReceptor Pharmacology - A Tribute to Norman Bowery. Adv Pharmacol. 2010 ; 58: 373-396
69. van Noorden MS, van Dongen LC, Zitman FG, Vergouwen TA. Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known. Gen Hosp Psychiatry. 2009 ; 31: 394-396
70. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992 ; 49: 876-880
71. Wojtowicz JM, Yarema MC, Wax PM. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review. CJEM. 2008 ; 10: 69-74
72. Wong CG, Chan KF, Gibson KM, Snead OC. Gamma-hydroxybutyric acid: neurobiology and toxicology of a recreational drug. Toxicol Rev. 2004 ; 23: 3-20 (Pubitemid 40484568)
73. Zack M, Poulos CX, Woodford TM. Diazepam dose-dependently increases or decreases implicit priming of alcohol associations in problem drinkers. Alcohol Alcohol. 2006 ; 41: 604-610 (Pubitemid 44742377)
74. Zack M, Toneatto T, MacLeod CM. Implicit activation of alcohol concepts by negative affective cues distinguishes between problem drinkers with high and low psychiatric distress. Abnorm Psychol. 1999a ; 108: 518-531 (Pubitemid 29400107)
75. Zack M, Toneatto T, MacLeod CM. Clinical use of benzodiazepines and decreased memory activation in anxious problem drinkers. Alcohol Clin Exp Res. 1999b ; 23: 174-182 (Pubitemid 29068484)